Cargando…

Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer

BACKGROUND: Pancreatic cancer is a rapidly fatal disease with gemcitabine remaining the first-line therapy. We performed a genotype–phenotype association study to identify biomarkers for predicting gemcitabine treatment outcome. MATERIALS AND METHODS: We selected the top 200 single nucleotide polymo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Liang, Zhang, Jian-Wei, Jenkins, Gregory, Xie, Fang, Carlson, Erin E., Fridley, Brooke L., Bamlet, William R., Petersen, Gloria M., McWilliams, Robert R., Wang, Liewei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083195/ https://www.ncbi.nlm.nih.gov/pubmed/27749787 http://dx.doi.org/10.1097/FPC.0000000000000241

Ejemplares similares

Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic Adenocarcinoma
por: Ellsworth, Katarzyna A., et al.
Publicado: (2013)

Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers
por: Li, Liang, et al.
Publicado: (2009)

Identifying the Genetic Variation of Gene Expression Using Gene Sets: Application of Novel Gene Set eQTL Approach to PharmGKB and KEGG
por: Abo, Ryan, et al.
Publicado: (2012)

Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines
por: Li, Liang, et al.
Publicado: (2014)

Genetic Association Studies of Copy-Number Variation: Should Assignment of Copy Number States Precede Testing?
por: Breheny, Patrick, et al.
Publicado: (2012)

A Pilot Study of Blood-Based Methylation Markers Associated With Pancreatic Cancer
por: Jansen, Rick J., et al.
Publicado: (2022)

Localization of Association Signal from Risk and Protective Variants in Sequencing Studies
por: Brisbin, Abra, et al.
Publicado: (2012)

FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer
por: Hou, Junmei, et al.
Publicado: (2012)

Use of the gamma method for self-contained gene-set analysis of SNP data
por: Biernacka, Joanna M, et al.
Publicado: (2012)

Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation
por: Cairns, Junmei, et al.
Publicado: (2018)

Analysis of variation in NF-κB genes and expression levels of NF-κB-regulated molecules
por: Liu-Mares, Wen, et al.
Publicado: (2007)

Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system
por: Jiang, Jing, et al.
Publicado: (2013)

Leukocyte DNA Methylation Signature Differentiates Pancreatic Cancer Patients from Healthy Controls
por: Pedersen, Katrina S., et al.
Publicado: (2011)

Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma
por: Mehner, Christine, et al.
Publicado: (2015)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Self-Contained Gene-Set Analysis of Expression Data: An Evaluation of Existing and Novel Methods
por: Fridley, Brooke L., et al.
Publicado: (2010)

Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study
por: Niu, Nifang, et al.
Publicado: (2012)

Factors influencing receptivity to future screening options for pancreatic cancer in those with and without pancreatic cancer family history
por: Breitkopf, Carmen Radecki, et al.
Publicado: (2012)

Association between Alcohol Consumption, Folate Intake, and Risk of Pancreatic Cancer: A Case-Control Study
por: Yallew, Winta, et al.
Publicado: (2017)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization
por: Yan, Tao, et al.
Publicado: (2017)

Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment
por: Wu, Lin-Wen, et al.
Publicado: (2019)

Predictive Modeling of In Vivo Response to Gemcitabine in Pancreatic Cancer
por: Lee, James J., et al.
Publicado: (2013)

Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer
por: Damaraju, Vijaya L, et al.
Publicado: (2007)

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
por: Samanta, Kamalika, et al.
Publicado: (2019)

Barriers and opportunities for gemcitabine in pancreatic cancer therapy
por: Beutel, Alica K., et al.
Publicado: (2023)

Determinants of gemcitabine response in pancreatic cancer: are we there?
por: Fitzpatrick, Orla M., et al.
Publicado: (2023)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine
por: Yu, Yue, et al.
Publicado: (2019)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer
por: Mahajan, Ujjwal M, et al.
Publicado: (2019)

Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer
por: Aggarwal, Sahil, et al.
Publicado: (2013)

Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein
por: Lin, Xiansheng, et al.
Publicado: (2016)

Phase II study of gemcitabine in patients with advanced pancreatic cancer.
por: Carmichael, J., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_6qmljvmma47okdg7ti0opmdhk9